Kontessis P S, Paraskevopoulos A, Papageorgiou I, Rappini P, Digenis G E, Antsaklis A, Zerefos N
Renal Unit, University of Athens Medical School, Alexandra Hospital, Greece.
Am J Kidney Dis. 1995 Nov;26(5):781-4. doi: 10.1016/0272-6386(95)90442-5.
Recombinant human erythropoietin (r-HuEPO) is broadly accepted as treatment for anemia in dialysis and nondialysis patients with chronic renal failure, but data regarding the safety and efficacy of this drug in pregnancy are limited. Maternal and fetal problems have been reported to be associated with anemia during pregnancy. On the other hand, anemia is a frequent feature of systemic lupus erythematosus. We report the successful use of r-HuEPO in a young woman with lupus nephritis complicated by severe anemia during pregnancy. Additional studies should be encouraged to confirm the safety of r-HuEPO therapy during pregnancy.
重组人促红细胞生成素（r-HuEPO）被广泛认可为治疗慢性肾衰竭透析和非透析患者贫血的药物，但关于该药物在孕期安全性和有效性的数据有限。据报道，孕期贫血与母婴问题相关。另一方面，贫血是系统性红斑狼疮的常见特征。我们报告了一名患有狼疮性肾炎并在孕期并发严重贫血的年轻女性成功使用r-HuEPO的案例。应鼓励开展更多研究以证实r-HuEPO治疗在孕期的安全性。
